Clinical Trials Browser

Phase 1 × INDUSTRY × eflapegrastim × Clear all

NCT04187898 2024-09-19

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Phase 1 Completed

Breast Neoplasms, Neutropenia

NCT03135951 2020-11-13

Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy

Phase 1 Completed

Breast Neoplasms